Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

Sensory axons (magenta) peppered with ligands for ‘killer’ immune receptors (green)

The scheme was created to help develop the next wave of world-class research and innovation leaders in academia and business. Science Minister Amanda Solloway announced a total of nearly 100 new Fellows, who will share in £113 million funding, with individual researchers receiving up to £1.5 million.

This fellowship gives me the support and resources I need to realise my vision of enhancing the body's own ability to repair and resolve painful nerve injury.
- Dr Alexander Davies

During his fellowship, Dr Davies and his team will investigate exactly how ‘killer’ cells target injured nerves, with the aim of developing a targeted immune therapy for neuropathic pain that avoids the side effects of existing treatments.

Chronic pain, often because of nerve injury, affects as many as 1 in 3 adults in the UK and costs the economy billions of pounds every year in treatment and lost productivity. The currently used drugs may either be ineffective or pose significant side effects for patients.

Alex's previous research has shown that injured nerves display distress signals that are received by specialised ‘killer’ cells of the immune system. The activity of these killer immune cells in turn appears to help relieve the pain of a nerve injury.

Professor Dame Ottoline Leyser, UKRI Chief Executive, said: ‘I am delighted that UKRI is able to support the next generation of research and innovation leaders through our Future Leaders Fellowship programme. The new Fellows announced today will have the support and freedom they need to pursue their research and innovation ideas, delivering new knowledge and understanding and tackling some of the greatest challenges of our time.’  

Similar stories

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'

Discovery of gene involved in chronic pain creates new treatment target

Our researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord. This is helping them to understand an important mechanism underlying chronic pain in humans, and provides a new treatment target.

Lymph nodes reveal more about mechanisms of autoimmunity

Two recent papers show that studying lymph nodes reveals details of the mechanisms of autoimmunity.

Multiple heart-related conditions linked to triple dementia risk, regardless of genetics

Having multiple conditions that affect the heart is linked to a greater risk of dementia than having high genetic risk, according to a large-scale new study.

NDCN research presented at Myasthenia Gravis conference

The 14th Quinquennial Myasthenia Gravis Federation of America International Conference was recently held in Miami with 450 delegates attending in person, including over 100 from industry.

Magnetic signatures of the brain characterised in UK Biobank imaging study

A study published this week in Nature Neuroscience demonstrates how studying the magnetic properties of tissue may provide a unique window into brain health and disease.